$VRDN News

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - Slideshow

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31

Needham Reiterates Buy on Viridian Therapeutics, Maintains $32 Price Target

Viridian Therapeutics Receives FDA Approval For Lumvoa For The Treatment Of Thyroid Eye Disease; Co. Plans To Launch Lumvoa Immediately

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Viridian Therapeutics Strikes Commercial Manufacturing Services Agreement With WuXi Biologics To Produce, Supply Veligrotug Drug Substance, Drug Product

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease - Slideshow

Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising

Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $34